Monday, September 25, 1995
Among the hallway topics at last week's BioPartnering Europe conference in London, one could hear debated whether Europe was on the brink of creating a critical mass of homegrown biotechnology ventures. As is usually the case, commentary ranged from the optimistic to the skeptical. To provide a flavor of the emerging biotech enterprise in Europe, BioCentury this week offers profiles of three early-stage companies that are pursuing chimeric technology, gene therapy, and "combinatorial biology".
Emerging Company Profile
XTL's chimeric technology
When Martin Becker joined XTL Biopharmaceuticals Ltd. as President
and CEO in November 1994 from Syntex Corp., XTL had technology but no business
strategy. Becker has spent the past few months focusing the company's efforts
on the use of its chimeric animal technology to develop human monoclonal antibodies
and the creation of improved animal models that can be used in-house and in
conjunction with corporate partners to develop improved lead compounds.